HomeCompareKSBI vs JNJ

KSBI vs JNJ: Dividend Comparison 2026

KSBI yields 1.40% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KSBI wins by $14.88M in total portfolio value
10 years
KSBI
KSBI
● Live price
1.40%
Share price
$81.00
Annual div
$1.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.91M
Annual income
$13,109,333.93
Full KSBI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KSBI vs JNJ

📍 KSBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKSBIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KSBI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KSBI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KSBI
Annual income on $10K today (after 15% tax)
$118.58/yr
After 10yr DRIP, annual income (after tax)
$11,142,933.84/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KSBI beats the other by $11,138,947.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KSBI + JNJ for your $10,000?

KSBI: 50%JNJ: 50%
100% JNJ50/50100% KSBI
Portfolio after 10yr
$7.47M
Annual income
$6,557,011.66/yr
Blended yield
87.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KSBI
No analyst data
Altman Z
-0.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KSBI buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKSBIJNJ
Forward yield1.40%2.13%
Annual dividend / share$1.13$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$14.91M$30.3K
Annual income after 10y$13,109,333.93$4,689.40
Total dividends collected$14.75M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KSBI vs JNJ ($10,000, DRIP)

YearKSBI PortfolioKSBI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,979$279.01$10,592$272.30+$387.00KSBI
2$12,320$572.58$11,289$357.73+$1.0KKSBI
3$14,383$1,200.97$12,123$472.89+$2.3KKSBI
4$18,011$2,620.76$13,141$629.86+$4.9KKSBI
5$25,406$6,134.06$14,408$846.81+$11.0KKSBI
6$43,357$16,172.97$16,021$1,151.60+$27.3KKSBI
7$97,982$51,589.71$18,122$1,588.22+$79.9KKSBI
8$322,759$217,918.16$20,930$2,228.20+$301.8KKSBI
9$1,687,102$1,341,749.55$24,792$3,191.91+$1.66MKSBI
10$14,914,533$13,109,333.93$30,274$4,689.40+$14.88MKSBI

KSBI vs JNJ: Complete Analysis 2026

KSBIStock

KS Bancorp, Inc. operates as the bank holding company for KS Bank, Inc. that provides a range of community banking services to consumers and businesses. It offers personal deposit accounts, such as checking, savings, money market, and individual retirement accounts, as well as certificates of deposit; loan products, including vehicle, boat and marine, recreational, deposit/investment secured, student, debt consolidation, and home equity loans, as well as home equity lines of credit; and credit cards. The company also provides business checking and savings, and payroll card accounts; construction loans, such as builders' speculative and pre-sale and commercial builder loans; commercial loans, including equipment, facilities purchase, debt refinancing, and real estate loans; and seasonal cash needs, inventory financing, and receivables financing lines of credit. In addition, it offers merchant, payroll, cash management, and remote deposit services; and mortgage services, including home purchase, home refinance, construction/permanent loans. Further, the company provides wealth management services comprising investment management, financial and retirement planning, trust and estate, and private banking services. It operates through nine full service branch offices located in Kenly, Goldsboro, Wilson, Garner, Selma, Clayton, Wendell, Four Oaks, and Smithfield, North Carolina. The company was incorporated in 1924 and is headquartered in Smithfield, North Carolina.

Full KSBI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KSBI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KSBI vs SCHDKSBI vs JEPIKSBI vs OKSBI vs KOKSBI vs MAINKSBI vs ABBVKSBI vs MRKKSBI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.